Brain Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been newly diagnosed with glioblastoma (a type of brain tumour), confirmed by laboratory testing of tumour tissue
• People who have had surgery to remove all or part of the tumour, or to take a small sample (biopsy)
• People aged 18 to 70 years old at the time of signing the consent form, of any gender
• People with a general health and functioning score of 60 or above on a standard medical scale called the KPS (confirm with trial site)
• People whose doctors expect them to live for at least 6 months
• People who are able to begin radiation therapy within 6 weeks after their surgery
• People whose blood, kidney, and liver test results fall within acceptable ranges — including adequate white blood cell counts, platelet levels, haemoglobin, kidney function, and liver enzyme levels (confirm with trial site for specific values)
• People who are able and willing to attend all required study visits and follow-up appointments
• People of childbearing potential who agree to use reliable contraception throughout the study and for 6 months after treatment ends; women of childbearing potential must also have a negative blood pregnancy test within 72 hours before the first dose
• People who voluntarily agree to take part and sign a consent form

Who may not be able to join:

• People who have previously received systemic cancer treatment (such as chemotherapy) targeting the same tumour
• People who have had radiation therapy to the head before
• People whose current glioblastoma developed from a previous lower-grade brain tumour
• People whose glioblastoma is a spread (metastasis) from a glioma that was originally in another part of the body
• People who are unable to have an MRI scan, or unable to have an MRI scan with contrast dye
• People who received a drug called bevacizumab or internal radiation treatment within one month before joining
• People who participated in another clinical trial within one month before joining
• People who experienced a serious injury or serious infection within one month before joining, including infections that required a hospital stay
• People with significant heart problems, including certain types of heart muscle disease, uncontrolled irregular heartbeat, severe heart failure, or a weakened pumping function of the heart (confirm with trial site for specific classifications)
• People who had a major surgical procedure (other than brain tumour surgery) within 4 weeks before joining
• People with a history of misusing substances such as illicit drugs
• People who have had another type of cancer within the past 5 years (exceptions may apply if the cancer was fully cured — confirm with trial site)
• People with HIV, AIDS, active hepatitis B, hepatitis C, or a combination of hepatitis B and C infections
• People who are allergic to a medicine called temozolomide, or who cannot take temozolomide for any other reason
• Women who are not breastfeeding but have a positive blood pregnancy test within 7 days before the first treatment; or people (of any gender) who are unwilling to use at least one acceptable form of contraception during the study and for 3 months after the last treatment
• People whom the trial investigators judge to have other conditions that could increase their risk from participating, or that make participation otherwise unsuitable

Important: Always verify eligibility with the trial site directly before applying.